Lack of a Fluoxetine Effect on Prednisolone Disposition and Cortisol Suppression

Pharmacotherapy

Volumn 24, Issue 4, 2004, Pages 482-487

  Carson, Stanley W ^a,b   Letrent, Kristen J ^a,c   Kotlyar, Michael ^a,d,e   Foose, George ^a,f   Tancer, Manuel E ^b,g  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c et al Publications   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f Pharmacotherapy/Formulary Consult   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

Author keywords

Cortisol; CYP3A4 isoenzyme inhibitors; Fluoxetine; Glucocorticoids; Prednisolone; Selective serotonin reuptake inhibitors

Indexed keywords

CYTOCHROME P450 3A4; DEXTROMETHORPHAN; FLUOXETINE; GLUCOCORTICOID; HYDROCORTISONE; NORFLUOXETINE; ORAL CONTRACEPTIVE AGENT; PREDNISOLONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; STEADY STATE;

ADOLESCENT; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; FLUOXETINE; GLUCOCORTICOIDS; HALF-LIFE; HUMANS; HYDROCORTISONE; ISOENZYMES; MALE; METABOLIC CLEARANCE RATE; PREDNISOLONE; TISSUE DISTRIBUTION;

EID: 1842427819     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.5.482.33344     Document Type: Article

References (44)

1. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000;85:11-28.
2. Catterson ML, Preskorn SH. Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol Toxicol 1996;78:203-8.
3. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29(suppl 1):S33-43.
4. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
5. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 2000;28:1187-91.
6. Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J Clin Pharmacol 2001;41:443-51.
7. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-48.
8. Brosen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991;32:136-7.
9. Shader RI, Greenblatt DJ, von Moltke LL. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 1994;14:375-6.
10. Nelson MH, Birnbaum AK, Remmel RP. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin reuptake inhibitors. Epilepsy Res 2001;44: 71-82.
11. Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol 2001;21:161-6.
12. von Moltke LL, Greenblatt DJ, Schmider J, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-91.
13. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479-86.
14. Wright CE, Lasher-Sisson TA, Steenwyk RC, Swanson CN. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992;12:103-6.
15. Potkin SG, Thyrum PT, Alva G, et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 2002;22: 174-82.
16. Glynn AM, Slaughter RL, Brass C, D'Ambrosio R, Jusko WJ. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther 1986;39:654-9.
17. Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ. Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. Clin Pharmacol Ther 1987;42:465-70.
18. Szefler SJ, Rose JQ, Ellis EF, Spector SL, Green AW, Jusko WJ. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol 1980;66:447-51.
19. Varis T, Backman JT, Kivisto KT, Neuvonen PJ. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clin Pharmacol Ther 2000;67:215-21.
20. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001;51:443-50.
21. Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clin Pharmacol Ther 1991;49:558-70.
22. Szefler SJ, Ellis EF, Brenner M, et al. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy J Allergy Clin Immunol 1982;69:455-60.
23. Ludwig EA, Slaughter RL, Savliwala M, Brass C, Jusko WJ. Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. Drug Intell Clin Pharm 1989;23:858-61.
24. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000;56:57-60.
25. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 1989;45: 366-72.
26. Imani S, Jusko WJ, Steiner R. Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers. Pediatr Transplant 1999;3:126-30.
27. Lee KH, Shin JG, Chong WS, et al. Time course of the changes in prednisolone pharmacokinetics after coadministration or discontinuation of rifampin. Eur J Clin Pharmacol 1993;45: 287-9.
28. Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. Biomed Pharmacother 1986;40: 301-8.
29. Bergrem H, Refvem OK. Altered prednisolone pharmacokinetics in patients treated with rifampicin. Acta Med Scand 1983;213:339-43.
30. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 1999;19:155-63.
31. Rose J, Jusko W. Corticosteroid analysis in biological fluids by high-performance liquid chromatography. J Chromatogr 1979;162:273-80.
32. Orsulak PJ, Kenney JT, Debus JR, Crowley G, Wittman PD. Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reversed-phase HPLC with ultraviolet detection. Clin Chem 1988;34:1875-8.
33. Chen ZR, Somogyi AA, Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 1990;12:97-104.
34. Anonymous. Guidance for industry: in vivo drug metabolism/drug interactions studies: study design, data analysis, and recommendations for dosing and labeling. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 1999.
35. Garg V, Jusko WJ. Bioavailability and reversible metabolism of prednisone and prednisolone in man. Biopharm Drug Dispos 1994;15:163-72.
36. Cassidy F, Ritchie JC, Verghese K, Carroll BJ. Dexamethasone metabolism in dexamethasone suppression test suppressors and nonsuppressors. Biol Psychiatry 2000;47:677-80.
37. Huizenga NA, Koper JW, de Lange P, et al. Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J Clin Endocrinol Metab 1998;83:47-54.
38. Ritchie JC, Belkin BM, Krishnan KR, Nemeroff CB, Carroll BJ. Plasma dexamethasone concentrations and the dexamethasone suppression test. Biol Psychiatry 1990;27:159-73.
39. Amsterdam JD, Fawcett J, Quitkin FM, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997;154:963-9.
40. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000;40:58-66.
41. Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol 1996;36:792-8.
42. Kotlyar M, Brewer ER, Golding M, Carson SW. Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. J Clin Psychopharmacol 2003;23: 652-6.
43. Slayter KL, Ludwig EA, Lew KH, Middleton E Jr, Ferry JJ, Jusko WJ. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1996;59:312-21.
44. Lew KH, Ludwig EA, Milad MA, et al. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993;54:402-14.